ArticleMedical mycology2025
Economic burden of fungal diseases in the United States.
Article in Medical mycology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Candida glabrata Emerges as the Most Common Cause of Candidemia: Analysis of a Large Hospital-Based Database, United States, 2016-2024.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- In Vitro and In Silico Investigations of Antifungal Activity of Ethyl Acetate Extracts of Various Species of Swertia Against Aspergillus fumigatus.Chemistry & biodiversity · 2026Article
- Yeast identification, antifungal susceptibility testing, andJournal of clinical microbiology · 2026Article
- Molecular architecture of the fungal-specific potassium channel TOK1.Nature communications · 2026Article
- Predicting Valley Fever Outbreaks: Novel Mechanistic Models Incorporating Climate and Ecological Interactions.bioRxiv : the preprint server for biology · 2026Article
- Expanding the Antimicrobial Toolbox with Therapeutic Viruses: Mechanisms, Pharmaceutical Formulation, and Translational Outlook.Pharmaceuticals (Basel, Switzerland) · 2026Review
- UnderstandingJournal of medical microbiology · 2026Review
- Tinea corporis and tinea cruris incidence, risk factors, and treatments in a cohort of 6.8 million patients with Medicaid, United States.Medical mycology · 2026Article
- Article
- Exploring fungal survival mechanisms: toward next-generation antifungal therapies against Candida spp.Archives of microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
We conservatively estimated the annual US fungal disease-related economic burden as $19.4 billion, including direct medical costs ($13.4 billion) of hospitalizations (n = 133 555) and outpatient visits (n = 13.4 million), $1.7 billion from absenteeism, and $4.3 billion from deaths (n = 7288). These findings underscore the need for fungal disease surveillance, treatment, and prevention efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.